• Explore /
  • Poster
  • / Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2).

Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2).

Abstract Video & Slides Poster

Authors

null

Colin Hardin

The Cancer and Hematology Centers, Grand Rapids, MI

Colin Hardin , Carl Gray , Silvana Novelli , Tuba Hacibeki̇roglu , Münci Yağcı , Ruemu Ejedafeta Birhiray , Ashish Risal , Manjusha Namuduri , Jingxian Cai , Melanie Ufkin , Min Zhu , Sushmita Mukherjee , Jurriaan Brouwer-Visser , Aafia Chaudhry , Hesham Mohamed , Srikanth R Ambati , Elżbieta Iskierka-Jażdżewska

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT06097364

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr TPS7099)

DOI

10.1200/JCO.2024.42.16_suppl.TPS7099

Abstract #

TPS7099

Poster Bd #

74a

Abstract Disclosures

Similar Posters

First Author: Ruemu Ejedafeta Birhiray

First Author: Kitsada Wudhikarn

First Author: Stefano Luminari

First Author: Timothy M Illidge